Navigation Links
Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
Date:11/12/2013

SAN DIEGO, Nov. 12, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced business and financial results for the third quarter ended September 30, 2013.

For the three months ended September 30, 2013, Orexigen reported a net loss of $18.6 million, or $0.19 per share, as compared to a net loss of $30.6 million, or $0.44 per share, for the third quarter of 2012.

Total operating expenses for the third quarter of 2013 were $19.4 million compared to $31.5 million for the third quarter of 2012. This overall decrease in operating expenses reflects a decrease in research and development expenses associated with the conduct of the Light Study, the Contrave® cardiovascular outcomes trial. As of September 30, 2013, Orexigen had $48.7 million in cash and cash equivalents and an additional $34.1 million in marketable securities, for a total of $82.8 million.

Orexigen indicated that 2013 change in cash, cash equivalents, and marketable securities is trending to the lower end of the guidance range.  Orexigen now projects 2013 net decrease in cash, cash equivalents, and marketable securities to be between $70 million and $75 million.  The Company will commence certain active pharmaceutical ingredient (API) purchases after the Light Study interim analysis, in order to fulfill Contrave launch order requirements, which will be subsequently reimbursed by its North American commercial partner, Takeda Pharmaceuticals, once final product is shipped.  With this updated guidance, Orexigen expects to end the year with approximately $62-$67 million in cash, cash equivalents, and marketable securities.

"This is an exciting time at Orexigen, as we make final preparations for the Light Study interim analysis," said Michael Narachi, Chief Executive Officer of Orex
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
2. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
3. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
4. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
11. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... SEATTLE, Wash. , Oct. 20, 2014 ... today that it will report its third quarter 2014 ... close of the U.S. financial markets. Following the announcement, ... conference call to discuss the results and provide a ... PDT). Access to the event can be obtained as ...
(Date:10/18/2014)... -- In a policy paper released today, ... lesbian, gay, bisexual and transgender (LGBT) civil rights ... Pre-Exposure Prophylaxis (PrEP). PrEP is any medical or ... of a disease or infection prior to exposure. ... combination currently approved for PrEP, which protects against ...
(Date:10/17/2014)... 2014  Hanger, Inc. (NYSE: HGR ) ... of operations for the quarter ended September 30, 2014, ... A conference call to discuss these results is scheduled ... 7, 2014. Those wishing to participate should call 1-877-662-6095. ... 2014 by dialing 1-855-859-2056 and referencing Conference ID # ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
... The " Peripheral Vascular & ... (Balloons, EVAR Stent Grafts, IVC Filter, IVUS & Angiography ... Accessory Devices) Global Trends & Competitive Analysis " ... and opportunities in North America, Europe, Asia and Rest ...
... 2012 Earlier today the federal district court denied our ... of our license to ship controlled substances from our Lakeland, ... noticed our appeal of this decision to the U.S. Court ... contingency plans will be immediately activated, and we will make ...
Cached Medicine Technology:MarketsandMarkets: Global Peripheral Vascular & Interventional Cardiology Devices Market worth $37.9 Billion by 2016 2MarketsandMarkets: Global Peripheral Vascular & Interventional Cardiology Devices Market worth $37.9 Billion by 2016 3
(Date:10/20/2014)... (PRWEB) October 20, 2014 With a ... Gov. Charlie Crist made a brief fundraising stop at ... on Thursday. , Fresh from a debate last night ... take the stage for the first seven minutes because ... former governor described the incident in one word: "weird." ...
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 ... joined Specialists in Obstetrics & Gynecology of Columbus, Inc., ... specialized women’s healthcare services to more than 100,000 patients ... care though all ages and stages of a women’s ... office locations in Westerville and Dublin. , ...
(Date:10/20/2014)... JZ Fitness, an independently operated wellness brand ... authorship, international lecturing and community wellness, created by Jenn ... of the JZ Fitness nutrition app, available on iTunes. ... of individuals on nutrition, Jenn Zerling (“JZ”) has developed ... calorie counting or cumbersome food logging. , ...
(Date:10/20/2014)... Myoderm announced today ... of their CentralSource service. Matthew will ... turnkey drug sourcing, distribution, and management service for ... years of industry experience, in both business development ... of their international success to help clients manage ...
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 National ... Ohio Chapter of the American Academy of Pediatrics (Ohio AAP, ... Administration (NHTSA) in encouraging parents of teen drivers to talk ... hit the road. , Motor vehicle crashes are the leading ... 2,055 teen drivers involved in fatal crashes, and 859 (42%) ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... depression, anxiety , , WEDNESDAY, Feb. 13 (HealthDay News) -- ... symptom relief are more likely to suffer cognitive shortfalls ... slowing down in the ability to process and remember ... rise in the rate of depression and anxiety. , ...
... year, millions of people are infected with noroviruses - commonly ... hours of vomiting and diarrhea. While most people recover in ... - in rare cases, especially among the elderly and infants ... of North Carolina School of Public Health have discovered that ...
... Judgment Against Widex and William Demant Companies, SALT ... SNCI ), a leading producer of advanced digital hearing ... number of press,releases related to a jury award of ... Group, Inc. v. Sonic Innovations,Inc., et al. While this ...
... The first genome-wide search for genes governing social behavior ... the amoebae Dictyostelium discoideum -- have more than 100 ... study by scientists at Rice University and Baylor College ... the journal Nature. It marks one of the first ...
... Senior Living Inc.,(NYSE: BKD ) announced today that ... 2007 financial results after the market closes on Wednesday,February ... to discuss,the results on February 28, 2008 at 10:00 ... (866) 845-7252 (from within the U.S.) or (706) 634-9069,(from ...
... (PHILADELPHIA) Scientists at The Wistar Institute have collaborated on ... to some of the deadliest cancers in humans. The culmination ... the development of new cancer therapies. , During much ... our cells exists in an inactive form, stored inside densely ...
Cached Medicine News:Health News:Marijuana Use Among MS Patients Raises Risk for Cognitive, Mood Problems 2Health News:Marijuana Use Among MS Patients Raises Risk for Cognitive, Mood Problems 3Health News:Vaccine for stomach flu may be possible, UNC research shows 2Health News:Sonic Innovations Not Included in Adverse Jury Verdict 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 2Health News:Microbial 'cheaters' help scientists ID 'social' genes 3Health News:Brookdale Announces Fourth Quarter and Full Year 2007 Release and Earnings Call 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 3